Chris Viehbacher, Biogen CEO (Sarah Merians Photography for Endpoints News)
Biogen gets $250M in Royalty Pharma deal for Phase 3 lupus program
Biogen is turning to Royalty Pharma for some cash in exchange for rights to a lupus program, the companies announced Wednesday.
The two have agreed …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
